There is a balm in Gilead: Idenix’s patent infringed but invalid

The Journal of Intellectual Property Law and Practice (JIPLP) has published an article by Darren Smyth on a decision by the Patents Court in Idenix Pharmaceuticals, Inc v Gilead Sciences, Inc & Others where Idenix unsuccessfully argued that a cited document constituting novelty-only prior art was not entitled to its priority date due to a procedural defect rather than its substantive disclosure.

To read the JIPLP article in full, click here.

Subscribe to The Patent Strategist newsletter

Thank you for your interest.

Subscribe to The Patent Strategist newsletter

Get expert insights and the top patent stories delivered straight to your inbox.